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Az összefoglaló célja, hogy megemlékezzünk Selye Jánosról,
az endokrinológusról, a stressz leghíresebb kutatójáról, és
röviden összefoglaljuk a szomatosztatin (SST), a ciszteamin
(CysA) és a pantethon (PAN) legfontosabb jellemzôit neu-
roendokrinológiai szempontból, amelyek szoros összefüg-
gésben álllnak tudományos munkájával. Emellett megem-
lítjük a kinurenin (KP) -útvonal néhány metabolitját is mint a
neuroendokrinológia néhány lehetséges célmolekuláját.
R. Guillemin és A. V. Schally jártak elôl az SST
felfedezésében az 1970-es években. Az SST-t fôként a
növekedésihormon-elválasztás inhibitoraként ismerjük,
emellett csökkenti a gyomosav és a pepszin felszabadulását
és a gastroduodenalis nyálkahártya véráramlását. Ezek a
hatások nagyon fontosak a peptikus fekély vérzésének
kórélettanában, ami összefügg a CysA által kiváltott per-
foráló duodenalis fekély kísérletes stresszmodelljével,
patkányban, amit Selye és Szabó fejlesztettek ki. A CysA a
természetben elôforduló duodenalis ulcerogen anyag, ami
SST-depléciót okoz a gyomornyálkahártyában és egyes agyi
régiókban. Az SST-depléció mellett a CysA adrenocorticalis
necrosist is okoz, ami kölcsönhatásra utal a centrális/peri -
fériás idegrendszer és a neuroendokrin rendszer között. A
CysA mellett képzôdô antioxidáns PAN hatása hasonló:
csökkenti az SST és a prolaktin szintjét az agykéregben és a
hypothalamusban az által, hogy a CysA testszerte felhal-
mozódik a sejteken belül. Új szempontként a KP részt vehet
a neuroendokrin folyamatok modulációjában: a glu-
tamátreceptorok különbözô agonistái és antagonistái sza -
bályozzák a hypothalamus-hypophysis-mellékvese tengelyt,
és a kinurénsav fokozza újszülött csibékben az anxiolyticus
stresszválaszt. A KP proinflammatorikus citokin által indukált
és a toxikus nehézolaj-szennyezôdés által kiváltott változásai
közvetetten hozzájárulnak a neuroendokrin zavarokhoz. 
Összességében nagyon fontos fejlôdés ment végbe a neu-
roendokrinológiában Selye elsô eredményei óta. Bár még
viszonylag kevés adatunk van a kinureninek potenciális
szerepérôl a neuroendokrinológiában, a már elért ered-
mények különösen értékesek és nagyon ígéretesek.
Kulcsszavak: szomatosztatin, ciszteamin, pantethin, 
kinurenin
The aim of this review is to commemorate Hans Selye,
endocrinologist, the most famous researchers of stress and
to briefly summarize the major features of somatostatin
(SST), cysteamine (CysA) and patethine (PAN) in neuroen-
docrinological aspect, which are closely related to his scien-
tific work. In addition, some metabolites of kynurenine path-
way (KP) were also mentioned in this paper, as new, possi-
ble target molecules in neuroendocrinology. 
R. Guillemin and A. V. Schally were the main pioneers of
the discovery of SST in the 1970’s. SST primarily is known
as an inhibitor of growth hormone secretion and additional-
ly reduces the gastric acid and pepsin release and also the
gastroduodenal mucosal blood flow. These effects are very
important in the pathophysiology of peptic ulcer bleeding,
which is related to the CysA-evoked perforating duodenal
ulcer experimental stress model in rats developed by Selye
and Szabo. CysA is a naturally occurring duodenal ulcero-
gen, which depletes SST in the gastric mucosa and certain
brain regions. Furthermore, in addition to depleting SST,
CysA also causes adrenocortical necrosis, suggesting an
interaction between the central/peripheral nervous system
and the neuroendocrine system. The antioxidant PAN, for-
mulated besides the CysA, has similar effects: it attenuates
the levels of SST and prolactin in the cerebral cortex and
hypothalamus through the accumulation of CysA within cells
throughout the body. As new perspectives the KP may be
involved in the modulation of neuroendrocrine processes:
different agonists and antagonists of glutamate receptors
regulate the hypothalamic-pituitary-adrenal axis and
kynurenic acid augments the anxiolytic stress responses in
neonatal chicks. The pro-inflammatory cytokine-induced
and the toxic heavy oil contaminations-evoked alterations in
the KP indirectly contribute to the development of neuroen-
docrine disorders. 
In summary, there have been highly important develop-
ments in neuroendocrinology since the early findings of
Selye. Although there are as yet relatively few data about
the potential role of kynurenines in neuroendocrinology, the
results already achieved are extremely noteworthy and
immensely promising.
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The hormone somatostatin (SST) was isolatedfrom the hypothalamus in the 1970’s1-3. It was
originally regarded only as an inhibitor of growth
hormone (GH) release (and was previously called
somatotropin release inhibiting factor), but it is now
known that SST has a number of biological effects.
Burgus et al. observed that the addition of crude
extracts of the ovine hypothalamus to anterior pitu-
itary cells maintained in vitro inhibited the secre-
tion of GH and they isolated a compound that
accounted for all the GH-release inhibiting activity
of the crude extract1. After sequencing and synthe-
sis the peptide displayed biological activity both in
vitro and in vivo. SST, a small cyclic peptide, exists
in two biologically active forms: SST-14 and SST-
28, which are produced by the alternative post-
translational cleavage of the single prehormone.
SST release can be stimulated by a variety of hor-
mones (growth hormone- and corticotropin-releas-
ing hormone, neurotensin), neuropeptides, neuro-
transmitters, cytokines, growth factors and nutrients
in several tissues4. On the other hand, the neuro-
transmitter GABA and opiates generally inhibit
SST secretion5. Inflammatory cytokines, such as
interleukin-1, tumor necrosis factor alpha and inter-
leukin-6, are potent stimulators of SST release6,
while transforming growth factor beta and leptin7
inhibit the secretion of the peptide. The develop-
ment of synthetic analogs has led to the effective
treatment of clinical disorders including acro -
megaly, hormone-secreting tumors of the gastroin-
testinal tract and portal hypertensive bleeding4. As
a general inhibitor of gastrointestinal endocrine
secretion, SST inhibits both gastric acid and pepsin
release8. Moreover, it combines these effects with a
reduction in gastroduodenal mucosal blood flow,
which appears to be important in the pathophysiol-
ogy of peptic ulcer bleeding. These results were
demonstrated by several experimental stress mod-
els; one of the earliest of these was the cysteamine-
evoked perforating duodenal ulcer model in rats
developed in 1973 by Selye and Szabo9.
Cysteamine (CysA) is a small aminothiol gener-
ated by hydrolysis of the lipid-lowering drug pan-
tethine (PAN), together with two pantothenic acids
(vitamin B5). It is assumed that CysA is involved in
the production of cholesterol and triglycerides by
means of its binding to inactivate sulfur-containing
amino acids in liver enzymes. Moreover, CysA is a
naturally occurring duodenal ulcerogen and has the
ability to cause adrenocortical necrosis too10. CysA
and its derivatives deplete SST in the gastric
mucosa, causing significant increases in gastric
acidity and pepsin activity, alterations that con-
tribute to the development of duodenal ulcer9. The
ulcerogenic activity of these derivatives is signifi-
cantly correlated with their SST-depleting activi-
ty11. In accordance with these findings, the admin-
istration of SST prevents the development of CysA-
induced duodenal ulcer. However, the effects of
CysA in causing duodenal ulcer and adrenal lesions
suggest an interaction between the central/peripher-
al nervous system and the neuroendocrine system.
In 1982, Palkovits et al. demonstrated that a single
subcutaneous (sc.) injection of CysA (300 mg/kg)
resulted in a quite selective SST depletion in the
brain. An approximately 70–80% decrease in SST
levels was observed in those areas where SST-pro-
ducing neurons (periventricular nucleus) and SST-
ergic nerve terminals (median eminence) are locat-
ed, whereas the CysA did not produce changes in
the levels of other neuropeptides12.
The naturally occurring antioxidant PAN is a
stable disulfide precursor of pantetheine. The latter
is an intermediate in the production of coenzyme A
(CoA) in the organism (Figure 1.). From a bio-
chemical aspect, the enzymatic cleavage of PAN
produces CysA (and later taurine) and pantothenic
acid. After absorption from the food, 4’-phospho-
pantetheine is reformed by the action of pantothen-
ate kinase, after which ribose and adenine mole-
cules attach to it in the mitochondrium to create
CoA or bind to acyl carrier protein13. CoA and acyl
carrier protein function as acyl or acetyl carriers.
CoA facilitates the transfer of acetyl groups from
pyruvate to oxaloacetate, thereby initiating the
Szent-Györgyi–Krebs (tricarboxylic acid) cycle.
CoA is involved in several ways in the fat metabo-
lism, including the synthesis, transportation and
degradation of fatty acids. Several clinical studies
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Figure 1.Metabolic pathway of pantethine (ImageCLEF
2011-Medical Datasheet)
have demonstrated its moderate benefits on dyslipi-
demic subjects14 and also its inhibition of platelet
aggregation, which offers an effective therapeutic
option for the treatment of patients with different
forms of atherosclerotic vascular disease15.
From a neuroendocrinological aspect, the
administration of PAN attenuates the levels of SST-
and prolactin-immunoreactivity in the cerebral cor-
tex and hypothalamus16 through the accumulation
of CysA within cells throughout the body. It has
therefore been suggested that this substance may be
a useful pharmacological tool for elucidation of the
role of SST in the central nervous system. The func-
tion of catecholaminergic pathways cannot be
excluded completely since PAN or possibly the
forming CysA inhibits dopamine beta-hydroxy-
lase17. In 1989, Sellini et al. observed that a single
high dose of PAN increased the levels of adreno-
corticotropic hormone and cortisol (still within the
normal range), but had no effect on the GH and Pro
levels. This might be explained by a PAN-induced
stimulus of the pituitary–adrenal axis or an
increased synthesis of acetylcholine18.
There is evidence that CysA and PAN have
behavior-modulating functions and other hormonal
effects too. CysA can more effectively diminish
locomotor, rearing and grooming activities than an
equimolar dose of PAN. PAN influences several
other behavioral responses in animals19: it stimu-
lates the food intake in satiated rats, depending
upon the stage of the circadian rhythm, but inhibits
the food intake in fasted animals17. This effect is
possibly mediated through the disinhibition of cen-
tral appete-regulating SST-ergic pathways. It influ-
ences shuttle box learning20 and causes locomotor
inhibition (4 h after sc. treatment) and activation
(24 h after repeated sc. injection) in open-field
test21, 22. It leads to the attenuation of SST-induced
barrel rotation23. From the aspect of passive avoid-
ance behavior, there is no effect after sc. adminis-
tration and merely a slight disruption after intrac-
erebroventricular (icv.) treatment21. CysA, and to a
lesser extent PAN, reduced the concentration of
noradrenaline and increased those of dopamine and
3,4-dihydroxyphenylacetic acid in the hypothala-
mus. Pantothenic acid itself did not influence either
the hypothalamic catecholamine concentrations or
the behavior of rats22.
Kynurenines, as ligands of glutamate (Glu)
receptors may also be important modulators of the
neuroendocrine system. In 1976, Coyle and
Schwarcz revealed that kainic acid (KA) is associ-
ated with lesions of the striatal neurons, as in
Huntington’s disease (HD) and it depletes SST24. In
1989, Beal et al. demonstrated that the striatal exci-
totoxin lesions caused by the injection of quinolin-
ic acid (QA), resulted in relative sparing of the SST
and neuropeptide-Y (NPY) levels in rats25. Cortical
injections of certain agonists acting at the Glu
receptors depleted the Glu and GABA levels, while
the SST- and NPY immunoreactivity were either
unchanged or significantly increased. Other N-
methyl-D-aspartate (NMDA) excitotoxins, such as
KA and alpha-amino-3-hydroxy-5-methyl-4-isoxa-
zolepropionic acid (AMPA) caused significant
decreases in the concentration of SST26. Chronic
QA-induced lesions resulted in similar alterations:
elevated SST and NPY concentrations and reduced
GABA, substance P-ir and choline acetyltrans-
ferase activity27. The pattern of selective neuronal
damage caused in the cerebral cortex by NMDA
receptor agonists was similar to that observed in
HD. However, there are contradictions, because
there were no changes in SST, NPY or SP-ir with
aging in the cerebral cortex or hippocampus follow-
ing QA-induced striatal lesions28, but there are dif-
ferent behavioral effects of KA- or QA-induced
striatal lesions29. 
Preclinical studies have indicated that the
kynurenine pathway (KP) may be involved in the
modulation of neuroendrocrine processes. Espe -
cially the function of kynurenic acid (KYNA) as a
new, potential neuroendocrine molecule is empha-
sized. The main branch (approx. 95%) of the tryp-
tophan (Trp) metabolism is the formation of
kynurenines. Trp may be converted to L-kynure-
nine (KYN) by Trp- or indoleamine 2,3-dioxyge-
nase (IDO) via a transition product. KYN serves as
a key molecule between the neurotoxic and neuro-
protective directions of the pathway. The neurotox-
ic QA is produced from KYN via additional toxic
metabolites, which generate toxic free radicals,
oxidative stress and lipid peroxidation, and hence
excitotoxicity. In contrast, the characteristically
neuroprotective KYNA is formed directly from
KYN catalyzed by kynurenine aminotransferase
(KAT) (Figure 2.)30. Most of the neuroprotective,
antiexcitotoxic effects of KYNA are explained by
the inhibition of excitatory amino acid receptors. It
has been proposed to act primarily as an antagonist
at ionotropic AMPA and KA receptors, and as a
noncompetitive antagonist at the strychnine-insen-
sitive glycine-binding site of the NMDA receptors.
KYNA can be an antagonist of the alpha7-nicotinic
acetylcholine receptors, and a ligand for the orphan
G protein-coupled receptors and the recently
revealed aryl hydrocarbon receptors31. There is
extensive literature on the role of the KP in differ-
ent neurological diseases. Its protective impacts are
emphasized in HD32, Parkinson’s disease33,
Ideggyogy Sz 2014;67(3–4):000–000. 3
migraine34, 35, multiple sclerosis36, 37, schizophre-
nia38, stroke39, 40 and epilepsy41, but its action in
endocrine/neuroendocrine mechanisms has not yet
been fully investigated. 
In 1985, Rogers and Evangelista observed that
leucine-stimulated insulin release from rat pancre-
atic islets can be inhibited by kynurenine metabo-
lites (3-hydroxykynurenine and 3-hydroxyan-
thranilic acid)42. The regulatory effects of QA were
investigated in ovariectomized, estradiol-primed
rats. It was shown that icv. administered QA
evoked an acute, dose-dependent increase of serum
luteinizing hormone concentrations, which was
blocked by KYNA. Brain morphologic distur-
bances were not detected in consequence of the
treatments43. The agonists and antagonists of Glu
receptors regulate the hypothalamic-pituitary-adre-
nal axis (HPA) by different subtypes of amino acid
receptors. Glu, KA and L-aspartate (Asp) signifi-
cantly diminished the release of corticotropin-
releasing hormone, while Asp and NMDA signifi-
cantly enhanced arginine-vasopressin release,
whereas this was decreased by KA and quisqualic
acid. KYNA completely abolished the effects of
Asp in connection with both neurohumoral activa-
tors44. A human study has indicated that cytokines
such as interferon- and interleukin-10 regulate the
expression of IDO in cells of hypothalamic and
pituitary origin in connection with sickness behav-
ior of patients45. In 2010, Oxenkrug observed simi-
lar results: the pro-inflammatory cytokines facili-
tate the activity of IDO, which shifts the Trp metab-
olism to the formation of kynurenines. These mole-
cules indirectly contribute to the development of
metabolic syndromes and age-associated neuroen-
docrine disorders via apoptotic, neurotoxic and pro-
oxidative effects (Figure 3.). A genetic predisposi-
tion to the presence of certain polymorphisms of
pro-inflammatory cytokine genes might lead to the
“superinduction” of IDO46. The anxiolytic effects of
KYNA were recently evaluated in neonatal chicks.
A stress model was developed by social isolation,
which was augmented by icv. corticotropin-releas-
ing hormone. The stress responses were decreased
by the icv. administration of Trp and (more effec-
tively) KYNA. Attenuated distress vocalization,
active wakefulness and increased time of sleeping
position were observed after the KYNA treatment.
Moreover, a depressed plasma corticosterone con-
centration was measured47. When the toxic rever-
berations of the heavy oil spill near the northwest
coast of Spain (2002) were examined seven years
after the disaster from the aspects of endocrine and
immunological alterations, the biomarker analyses
revealed a significantly increased plasma level of
cortisol, and decreased level of KYN and
CD16+56+lymphocytes in exposed vs. unexposed
individuals. More serious changes were observed in
the chronically contaminated subjects, which sug-
gested a chronic elevation of HPA activity and the
possibility of endocrine diseases48. 
In summary, it may be stated that there have
been highly important developments in neuroen-
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Figure 3. Relationship between kynurenines, metabolic
syndromes (MetS) and age-associated neuroendocrine
disorders (AAND) (Oxenkrug, G.F. Ann N Y Acad Sci,
2010)
Figure 2. Main pathway of tryptophan-kynurenine
metabolism
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docrinology since the early findings of Selye.
Although there are as yet relatively few data about
the potential role of kynurenines in neuroen-
docrinology, the results already achieved are
extremely noteworthy and immensely promising.
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